Ok....labelling is the only area that 'seems' to make sense - while I took severe primary IGF-1 (primary IGFD) to mean those are two interchangeable terms, it does look like this implies severe primary IGF-1 = severe primary IGFD. I only go on to say that since in the indications and usage part, INSM proceeds to say out of the blue "severe primary IGFD is defined by"....in which case, obviously same thing.
Oh well, I know I'm not the only one confused as I know there was an analyst that also put a 1.2 billion market value on. I guess the 240million is the true current market for these approvals.
Thus, we trade at $2.60, and not $5....not like that explains why TRCA is still at $7 though!
Market Data 
Markets 
AI
